CanBas Co Ltd (4575):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CanBas Co Ltd (4575) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12323
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:20
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CanBas Co Ltd (CanBas) is a clinical stage biopharmaceutical company that develops therapeutics for cancer. The company discovers and develops of novel therapeutics in the field of oncology targeting the cell cycle. It provides two clinical oncology programs, CBP501 and CBS9106 with mutually unique MoAs. CanBas product carries out development in CBP501; a modified synthetic peptide enhances the efficacy of cisplatin without adding toxicity. CanBas’ CBP501 is in US Phase II development for first-line treatment of late stage malignant pleural mesothelioma and non-small cell lung cancer. The company’s other drug candidates, CBS9106, an orally-active synthetic small molecule of molecular mass 420, is in preclinical stage, and CBS2400 program is currently in the lead optimization stage of development. It also develops techniques to determine the drug specific sensitivity of individual cancer from a patient. CanBas is headquartered in Numazu, Japan.

CanBas Co Ltd (4575) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Licensing Agreements 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd – Key Competitors 14
CanBas Co Ltd – Key Employees 15
CanBas Co Ltd – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Clinical Trials 17
Sep 11, 2017: Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017 17
Aug 30, 2017: Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress 18
Feb 21, 2017: Stemline Therapeutics Provides Update on SL-801 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
CanBas Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
CanBas Enters into Research Agreement with Fujifilm 10
CanBas Enters into Research Agreement with University of Shizuoka 11
Stemline Therapeutics Enters into Licensing Agreement with CanBas 12
Stemline Therapeutics Enters into Licensing Agreement with CanBas for CBS-9106 13
CanBas Co Ltd, Key Competitors 14
CanBas Co Ltd, Key Employees 15

List of Figures
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
CanBas Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[CanBas Co Ltd (4575):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Allied Irish Banks, Plc:企業のM&A・事業提携・投資動向
    Allied Irish Banks, Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Allied Irish Banks, Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • ITC Holdings Corp.:企業の発電所・SWOT分析2018
    ITC Holdings Corp. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Hydro-Quebec:電力:M&Aディール及び事業提携情報
    Summary Hydro-Quebec is a government-owned energy utility that generates, transmits and distributes electricity. The company specializes in renewable energy generation, using hydro sources and supports the development of electricity using other technologies such as wind energy and biomass. It genera …
  • Syros Pharmaceuticals Inc (SYRS):製薬・医療:M&Aディール及び事業提携情報
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company’s pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used t …
  • Energiekontor AG (EKT):企業の財務・戦略的SWOT分析
    Summary Energiekontor AG (Energiekontor) is a renewable energy company that develops and operates offshore wind farms. It offers services which include construction, designing, engineering, planning, operation, and management of wind farms. The company also provides project financing, project manage …
  • CorEnergy Infrastructure Trust Inc (CORR):企業の財務・戦略的SWOT分析
    CorEnergy Infrastructure Trust Inc (CORR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • McEwen Mining Inc.:企業の戦略・SWOT・財務情報
    McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report Summary McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PT Perusahaan Gas Negara (Persero) Tbk (PGAS):石油・ガス:M&Aディール及び事業提携情報
    Summary PT Perusahaan Gas Negara (Persero) Tbk (PGN) is a downstream energy that transmits and distributes natural gas. The company plans, constructs and develops downstream natural gas businesses and carries out processing, transportation, storage and trading of natural gas. It produces, trades and …
  • Neogen Corp (NEOG):企業の財務・戦略的SWOT分析
    Neogen Corp (NEOG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • TenCate Advanced Armour:企業の戦略・SWOT・財務分析
    TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report Summary TenCate Advanced Armour - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • AMTEC Corporation:企業の戦略・SWOT・財務情報
    AMTEC Corporation - Strategy, SWOT and Corporate Finance Report Summary AMTEC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Theravectys SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Theravectys SA (TheraVectys) is a clinical development biotech company that develops new generation therapeutic vaccines and immunotherapies. The company develops viral vectors vaccines to support body and prepare against future infections by pre-exposing immune system to partial, dead, inac …
  • China National Electronics Import & Export Corporation:戦略・SWOT・企業財務分析
    China National Electronics Import & Export Corporation - Strategy, SWOT and Corporate Finance Report Summary China National Electronics Import & Export Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company' …
  • Everspin Technologies Inc (MRAM):企業の財務・戦略的SWOT分析
    Everspin Technologies Inc (MRAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Ipsen SA (IPN):企業の財務・戦略的SWOT分析
    Ipsen SA (IPN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Royal Dutch Shell Plc (RDSA):石油・ガス:M&Aディール及び事業提携情報
    Summary Royal Dutch Shell Plc (Shell) is an integrated oil and gas company. The company explores for and produces oil and gas from conventional fields and sources such as tight rock, shale and coal formations. Its refining and petrochemical complexes across the world add value to its upstream produc …
  • Legian Beach Hotel
    Legian Beach Hotel - Strategy, SWOT and Corporate Finance Report Summary Legian Beach Hotel - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Theranexus SAS (ALTHX):製薬・医療:M&Aディール及び事業提携情報
    Summary Theranexus SAS (Theranexus) is a biotechnology company that discovers and develops drug combinations for safe and efficient neurological and psychiatric treatments. The company develops THN102, a pipeline product that comprises modafinil. It also offers THN02 for the treatment of sleepiness …
  • TriGranit Corporation:企業の戦略・SWOT・財務情報
    TriGranit Corporation - Strategy, SWOT and Corporate Finance Report Summary TriGranit Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • FitLife Brands, Inc.:戦略・SWOT・企業財務分析
    FitLife Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary FitLife Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆